Table 2 Demographic and clinical characteristics of < 50% responders and ≥ 50% responders in patients with high-frequency episodic (HFEM) or chronic migraine (CM)
Number (%) or mean ± SD | Number (%) or mean ± SD | |||||
|---|---|---|---|---|---|---|
HFEM | CM | |||||
< 50% responders | ≥50% responders | p-value | < 50% responders | ≥50% responders | p-value | |
Patients | 73 (35.1%) | 135 (64.9%) | 253 (38.6%) | 403 (61.4%) | ||
Age, yrs | 47.3 ± 10.2 | 48.6 ± 11.4 | 0.418 | 46.9 ± 11.9 | 48.3 ± 11.4 | 0.129 |
Females | 58 (79.4) | 100 (74.1) | 0.386 | 204 (80.6) | 313 (77.7) | 0.366 |
BMI | 226 ± 2.4 | 22.8 ± 2.9 | 0.549 | 23.8 ± 4.5 | 23.0 ± 3.5 | 0.020 |
BMI class | 0.370 | 0.192 | ||||
Underweight | 4 (6.9) | 4 (3.5) | 12 (5.5) | 22 (6.5) | ||
Normal | 45 (77.6) | 81 (71.1) | 147 (67.4) | 231 (67.7) | ||
Overweight | 9 (15.5) | 28 (24.5) | 41 (18.8) | 74 (21.7) | ||
Obesity | 0 | 1 (0.9) | 18 (8.3) | 14 (4.1) | ||
Disease duration, yrs | 29.6 ± 11.0 | 29.5 ± 13.0 | 0.971 | 29.5 ± 12.7 | 31.1 ± 12.7 | 0.094 |
MMDs/MHDs at baseline | 10.7 ± 2.1 | 11.0 ± 2.0 | 0.439 | 24.3 ± 5.7 | 23.4 ± 5.8 | 0.039 |
MOH | – | – | – | 220 (87.0) | 351 (87.1) | 0.958 |
MOH duration, yrs | – | – | – | 9.3 ± 10.4 | 8.9 ± 7.9 | 0.593 |
Monthly analgesic intake at baseline | 12.2 ± 5.2 | 13.0 ± 6.7 | 0.479 | 28.5 ± 23.0 | 26.7 ± 22.9 | 0.324 |
NRS score | 7.7 ± 1.3 | 7.4 ± 1.5 | 0.206 | 7.8 ± 1.3 | 7.8 ± 1.2 | 0.997 |
UP | 41 (56.9) | 76 (58.9) | 0.786 | 104 (42.4) | 197 (49.5) | 0.082 |
Pain quality | 0.562 | 0.948 | ||||
Pulsating | 46 (65.7) | 81 (64.3) | 162 (67.2) | 267 (68.5) | ||
Pressing/tightening | 22 (31.4) | 37 (29.4) | 72 (29.2) | 112 (28.7) | ||
Other | 2 (2.9) | 8 (6.3) | 7 (2.9) | 11 (2.8) | ||
UAs | 27 (38.0) | 53 (40.8) | 0.704 | 115 (47.5) | 211 (53.8) | 0.123 |
Allodynia | 28 (39.4) | 61 (46.9) | 0.307 | 143 (58.6) | 240 (60.8) | 0.589 |
Dopaminergic symptoms | 46 (64.8) | 100 (76.9) | 0.065 | 167 (69.0) | 250 (63.9) | 0.191 |
UP + allodynia | 11 (42.3) | 44 (57.9) | 0.169 | 59 (50.4) | 147 (63.6) | 0.024 |
UP + UAs | 7 (28.0) | 47 (61.8) | 0.007 | 55 (47.0) | 139 (60.4) | 0.017 |
UP + UAs + allodynia | 9 (52.9) | 38 (61.3) | 0.534 | 45 (57.0) | 129 (70.1) | 0.039 |
Triptan responders | 50 (70.4) | 89 (70.0) | 0.925 | 133 (57.6) | 240 (64.2) | 0.105 |
Concomitant prophylaxis | 34 (51.5) | 71 (55.9) | 0.668 | 148 (61.4) | 211 (53.6) | 0.058 |
Prior treatment failures | 4.0 ± 2.0 | 4.2 ± 2.3 | 0.537 | 5.0 ± 2.2 | 5.3 ± 2.5 | 0.132 |
BoNT/A respondersa | 6 (40.0) | 9 (60.0) | 0.792 | 10 (43.5) | 13 (56.5) | 0.851 |
≥ 1 comorbidity | 31 (42.5) | 71 (52.6) | 0.211 | 115 (45.4) | 194 (48.1) | 0.762 |
Psychiatric comorbidities | 13 (18.1) | 15 (11.5) | 0.199 | 60 (24.4) | 86 (21.6) | 0.403 |
HIT-6 score | 66.0 ± 7.3 | 64.6 ± 6.3 | 0.197 | 66.5 ± 8.5 | 66.1 ± 10.7 | 0.587 |